Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxintong for quality of life in non-valvular atrial fibrillation patients after PCI
ChiCTR2100046333Phase 4Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of naoxintong in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Fujian Provincial Hospital. Primary endpoints: SF-36 Health Survey at 6 months and Seattle Angina Questionnaire (SAQ) at 6 months. Started May 2021; status: recruiting.
02
Drugs
naoxintong
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100046333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046333.